As per Future Market Insights’ latest industry analysis, the valuation for the global antiepileptic drugs market is estimated to be around US$ 17.3 Bn in 2022, and is projected to exhibit growth at a CAGR close to 4.3% over the forecast period, with an estimated valuation to be around US$ 26.2 Bn in 2032.

Epilepsy is a condition that causes repeated seizures that are not brought on by localized or severe brain shocks. Epilepsy is linked to gradual impairments in cognitive functioning, neurological damage, and other cerebral impairments if it is left untreated. Antiepileptic medications (AEDs) are prescribed to patients who have epilepsy to reduce the frequency and/or severity of their seizures.

After headaches, epilepsy is the second most prevalent neurological disorder. Since it has a significant financial impact on the health care system and imposes a significant morbidity burden on both individuals and society, it is a major concern for public health. It is characterized by repeated seizures with cerebral etiology.

Numerous medicines used to treat epilepsy frequently result in severe poisonings. AEDs do not have a perfect pharmacokinetic profile, which makes them suitable for both therapeutic and toxicity monitoring. Currently, tailoring the dosage to the patient's specific requirements and keeping an eye on adequate blood concentrations is very advantageous for patients utilizing different AEDs.

The growing ageing population, rising burden of neurological conditions, and rising disposable income, are thus the factors driving the demand for the global antiepileptic drugs market.

Request a Sample of this Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-3341

Key Takeaways from Market Study

• Second generation of antiepileptic drugs are the leading segment as drug generation, and hold approximately 53.4% market share in 2021. In comparison to first-generation medications, second generation AEDs have a lower risk of teratogenesis and a more favorable side-effect profile.
• Oral route of administration segment is set to lead in terms of route of administration of antiepileptic drugs with a market share of around 62.2% in 2021, owing to its ease of administration in pediatric and geriatric patients.
• By distribution channel, retail pharmacies are leading in the global antiepileptic drugs market, and are expected to continue to do so with a projected CAGR of 4.6% during the forecasted years.
• North America is considered as the leading region with a value share of 43.6% in 2021, owing to the high prevalence of neurological diseases in the region.

“Rising prevalence of neurological and mood disorders has called for innovations within the antiepileptic drugs market sphere,” says an analyst of Future Market Insights.

Competition

Key market leaders are concentrating on receiving regulatory agency approvals, which is anticipated to propel the expansion of the worldwide antiepileptic drugs market. Key players are coming up with new drug profiles to widen their portfolio presence.

For instance:

• Pfizer, Inc. reported in July 2019 that the US Food and Drug Administration has approved the first Lyrica (pregabalin) generics for use as an adjunctive therapy for the management of partial onset seizures in patients aged 17 and older.
• In August 2021, Eisai Co., Ltd. announced that the National Medical Products Administration in China had granted its internally discovered and developed anti-epileptic drug (AED) Fycompa® two additional approvals as "a monotherapy for partial-onset seizures" and "an adjunctive treatment / a monotherapy for pediatric indication for partial onset seizures in patients with epilepsy 4 years of age and older."

Antiepileptic Drugs Market: Key player

Some of the major key players in antiepileptic drugs market are following  Abbott Laboratories, Cephalon, Inc, Sunovion Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A. and UCB Pharma Ltd. GlaxoSmithKline plc,, Johnson & Johnson, Novartis AG, Pfizer, Inc.,

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also includes projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

Antiepileptic drugs market: Segmentation

Global Antiepileptic drugs market can be segmented by Drug class, Therapeutics use, Routes of administration, distribution channel and regional.

Segmentation by Drug class

• Phenytoin (Dilantin, Phenytek)
• Carbamazepine (Carbatrol)
• Oxycarbazepine (Trileptal)
• Valproate (Depakote)
• Topiramate (Topamax)
• Ethosuximide (Zarontin)
• Primidone (Mysoline)
• Phenobarbital (Luminal)
• Lamotrigine (Lamictal)
• Pregabalin (Lyrica)
• Rufinamide (Banzel/Inovelon)
• Levetiracetam (Keppra)
• Ezogabine/retigabine (Trobalt/Potiga)
• Lacosamide (Vimpat)
• Eslicarbazepine acetate (Aptiom)
• Zonisamide (Zonegran)
• Perampanel (Fycompa)

Segmentation by Therapeutic uses

• Partial
• Generalized

Segmented by Distribution Channel

• Retail Pharmacies
• Hospitals pharmacies
• Drug-store
• Mail order pharmacies
• Online\e-commerce

Segmented by geography

• North America
• Latin America
• Europe
• APAC
• The Middle East and Africa